198 related articles for article (PubMed ID: 8093812)
1. V-erbA requires auxiliary proteins for dominant negative activity.
Hermann T; Hoffmann B; Piedrafita FJ; Zhang XK; Pfahl M
Oncogene; 1993 Jan; 8(1):55-65. PubMed ID: 8093812
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein P75gag-v-erbA represses thyroid hormone induced transcription only via response elements containing palindromic half-sites.
Wahlström GM; Harbers M; Vennström B
Oncogene; 1996 Aug; 13(4):843-52. PubMed ID: 8761306
[TBL] [Abstract][Full Text] [Related]
3. The v-erbA oncogene requires cooperation with tyrosine kinases to arrest erythroid differentiation induced by ligand-activated endogenous c-erbA and retinoic acid receptor.
Schroeder C; Gibson L; Beug H
Oncogene; 1992 Feb; 7(2):203-16. PubMed ID: 1347913
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of transformation by v-ErbA: substitution for steroid hormone receptor function in self renewal induction.
Bauer A; Ulrich E; Andersson M; Beug H; von Lindern M
Oncogene; 1997 Aug; 15(6):701-15. PubMed ID: 9264411
[TBL] [Abstract][Full Text] [Related]
5. c-ErbA, but not v-ErbA, competes with a putative erythroid repressor for binding to the carbonic anhydrase II promoter.
Rascle A; Ghysdael J; Samarut J
Oncogene; 1994 Oct; 9(10):2853-67. PubMed ID: 7916146
[TBL] [Abstract][Full Text] [Related]
6. Modulation of normal erythroid differentiation by the endogenous thyroid hormone and retinoic acid receptors: a possible target for v-erbA oncogene action.
Schroeder C; Gibson L; Zenke M; Beug H
Oncogene; 1992 Feb; 7(2):217-27. PubMed ID: 1347914
[TBL] [Abstract][Full Text] [Related]
7. Requirements for repression of retinoid X receptor by the oncoprotein P75gag-v-erbA and the thyroid hormone receptors.
Wahlström GM; Vennström B
Mol Endocrinol; 1998 May; 12(5):645-53. PubMed ID: 9605927
[TBL] [Abstract][Full Text] [Related]
8. Requirement for the C-terminal domain of the v-erbA oncogene protein for biological function and transcriptional repression.
Forrest D; Muñoz A; Raynoschek C; Vennström B; Beug H
Oncogene; 1990 Mar; 5(3):309-16. PubMed ID: 1969136
[TBL] [Abstract][Full Text] [Related]
9. Modulation of thyroid hormone action by mutant thyroid hormone receptors, c-erbA alpha 2 and peroxisome proliferator-activated receptor: evidence for different mechanisms of inhibition.
Meier-Heusler SC; Zhu X; Juge-Aubry C; Pernin A; Burger AG; Cheng SY; Meier CA
Mol Cell Endocrinol; 1995 Jan; 107(1):55-66. PubMed ID: 7796935
[TBL] [Abstract][Full Text] [Related]
10. Dimerization of v-erbA on inverted repeats.
Zubkova I; Subauste JS
Biochem Biophys Res Commun; 2002 May; 294(1):35-41. PubMed ID: 12054736
[TBL] [Abstract][Full Text] [Related]
11. V-erbA and c-erbA proteins enhance transcriptional activation by c-jun.
Sharif M; Privalsky ML
Oncogene; 1992 May; 7(5):953-60. PubMed ID: 1349165
[TBL] [Abstract][Full Text] [Related]
12. Functional domains of the v-erbA protein necessary for oncogenesis are required for transcriptional activation in Saccharomyces cerevisiae.
Smit-McBride Z; Privalsky ML
Oncogene; 1993 Jun; 8(6):1465-75. PubMed ID: 8099219
[TBL] [Abstract][Full Text] [Related]
13. Roles of v-erbA homodimers and heterodimers in mediating dominant negative activity by v-erbA.
Yen PM; Ikeda M; Brubaker JH; Forgione M; Sugawara A; Chin WW
J Biol Chem; 1994 Jan; 269(2):903-9. PubMed ID: 7904604
[TBL] [Abstract][Full Text] [Related]
14. The erbA oncogene represses the actions of both retinoid X and retinoid A receptors but does so by distinct mechanisms.
Chen HW; Privalsky ML
Mol Cell Biol; 1993 Oct; 13(10):5970-80. PubMed ID: 8105369
[TBL] [Abstract][Full Text] [Related]
15. Constitutive transactivation by the thyroid hormone receptor and a novel pattern of activity of its oncogenic homolog v-ErbA in Xenopus oocytes.
Nagl SB; Nelson CC; Romaniuk PJ; Allison LA
Mol Endocrinol; 1995 Nov; 9(11):1522-32. PubMed ID: 8584030
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the thyroid hormone response element in the skeletal alpha-actin gene: negative regulation of T3 receptor binding by the retinoid X receptor.
Muscat GE; Griggs R; Downes M; Emery J
Cell Growth Differ; 1993 Apr; 4(4):269-79. PubMed ID: 8388243
[TBL] [Abstract][Full Text] [Related]
17. The leukaemia oncogene v-erbA: a dominant negative version of ligand dependent transcription factors that regulates red cell differentiation?
Ghysdael J; Beug H
Cancer Surv; 1992; 14():169-80. PubMed ID: 1358441
[TBL] [Abstract][Full Text] [Related]
18. Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency.
Meier CA; Parkison C; Chen A; Ashizawa K; Meier-Heusler SC; Muchmore P; Cheng SY; Weintraub BD
J Clin Invest; 1993 Oct; 92(4):1986-93. PubMed ID: 8408652
[TBL] [Abstract][Full Text] [Related]
19. Functional interaction between the two zinc finger domains of the v-erb A oncoprotein.
Hall BL; Bonde BG; Judelson C; Privalsky ML
Cell Growth Differ; 1992 Apr; 3(4):207-16. PubMed ID: 1355356
[TBL] [Abstract][Full Text] [Related]
20. Identification of DNA binding sites for the V-erbA oncoprotein, the viral homolog to thyroid hormone receptor alpha.
Harbers M; Wahlström GM; Vennström B
J Steroid Biochem Mol Biol; 1998 Nov; 67(3):181-91. PubMed ID: 9879977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
